Silence Therapeutics PLC (SLN)
Silence Therapeutics plc is a biotechnology company whose Nasdaq-listed security is an American depositary receipt representing common stock. The company focuses on discovering and developing RNA interference, or siRNA, molecules designed to reduce the expression of specific target genes. Its research programs span hematology, cardiovascular disease, and rare diseases. The pipeline includes Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, as well as SLN548 for complement-mediated renal diseases. Additional candidates include Zerlasiran (SLN360) for cardiovascular disease linked to elevated lipoprotein(a), SLN312 for dyslipidemia, SLN365 for hypercholesterolemia, and SLN098 for obesity. Incorporated in 1994, the company was previously known as SR Pharma plc and adopted its current name in May 2007. Silence Therapeutics is headquartered in London, United Kingdom.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SLN
|
$8.49
|
-21.7% Downside
|
Overvalued
|
$29.17
|
168.8% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-6.9x
|
10.5x
|
616.5x
|
495.5 M
|
447.3 M
|
0.0%
|
58.1%
|
-12.8
|
—
|
87.4%
|
